Jinwon Life Sciences Signs $1.8 Million Plasmid DNA Supply Contract

Jinwon Life Sciences announced on the 2nd that it has signed a plasmid DNA pharmaceutical supply contract worth 1.8 million dollars with a contract development and manufacturing organization (CDMO) company located in the United States.

The name of the contracting party cannot be disclosed in accordance with a contract clause that requires confidentiality. When converted to Korean won, the contract amount is approximately 2.5 billion won.

Park Young-geun, CEO of Jinwon Life Sciences, said, “The demand for plasmid DNA necessary for the production of cell and gene therapies had slowed during the COVID-19 pandemic but is recovering. Based on the high-quality plasmid DNA supply capabilities of our subsidiary VGXI’s new factory built in the Daeson Technology Park in Conroe, Texas, USA, we are actively conducting sales activities and expect steady orders to continue.”